Abstract
A series of some newly methylsulfanyl-triazoloquinazoline derivatives (1–21) have been tested against Coxsackievirus B4 and Adenovirus type 7. The antiviral activity of the titled compounds against Coxsackie B4 and Adeno type 7 was evaluated in BGM and Hep-2 cell lines. Compounds 4, 5, and 6 represent the most populated set of compounds obtained during this study, and 4 and 6 in particular were found to display the highest activities against Coxsackie B4 and exhibited good effect against Adeno type 7. The % of reduction in the case of Coxsackie B4 titer was 63.3 % (4, 6) and 83.3 % (5), while in Adeno type 7 titer was 63.3, 50, and 66.6 % for 4, 5, and 6, respectively.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
